Pulmonary hypertension in patients with sarcoidosis: A single-center experience

**Deniz Kaptan Özen, Bülent Mutlu*, Derya Kocakaya**, Burak Turan, Sena Sert Şekerci, Berrin Ceyhan**
Department of Cardiology, Derince Training and Research Hospital; Kocaeli-Turkey
*Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital; Istanbul-Turkey
Departments of *Cardiology, and **Pneumology, Faculty of Medicine, Marmara University; Istanbul-Turkey

**ABSTRACT**

**Objective:** Sarcoidosis is a systemic granulomatous disease rarely complicated by pulmonary hypertension (PH). The prevalence of PH in sarcoidosis is unclear and has differences between ethnic groups. This study aimed to investigate the prevalence and predictors of PH in a Turkish cohort.

**Methods:** The study included 55 patients with biopsy-proven sarcoidosis in a single center. All patients underwent detailed transthoracic echocardiography (TTE) to assess the probability of PH as recommended. Right heart catheterization (RHC) was performed for patients with intermediate–high risk of PH. Patients with mean pulmonary artery pressure >20 mm Hg by RHC were defined as PH. Demographic and clinical characteristics, laboratory data, spirometry, 6-min walk test, and TTE were compared between low and intermediate–high risk PH groups.

**Results:** The probability of PH was low with 47 patients. Eight patients had intermediate–high probability of PH, and two of them refused to undergo RHC. Of six intermediate–high probability patients, three had PH, and all of them had post-precapillary PH. The prevalence of PH in sarcoidosis was 5.5% (3/55). Six-minute walk distance (6 MWD) and diastolic parameters (E/A ratio, E' wave, and left atrial volume) were significantly lower, and New York Heart association class and N-terminal probrain natriuretic peptide (NT-proBNP) level were higher in intermediate–high risk PH patients compared with low-risk PH patients.

**Conclusion:** The frequency of PH in sarcoidosis was 5.5% in a Turkish cohort. NT-proBNP, 6 MWD, diastolic function parameters, and myocardial strain parameters can be useful predictors of PH in patients with sarcoidosis, besides known echocardiographic parameters.

**Keywords:** brain natriuretic peptide, sarcoidosis, 6-minute walk test, pulmonary hypertension

Cite this article as: Kaptan Özen D, Mutlu B, Kocakaya D, Turan B, Sert Şekerci S, Ceyhan B. Pulmonary hypertension in patients with sarcoidosis: A single-center experience. Anatol J Cardiol 2021; 25: 36-41

---

**Introduction**

Sarcoidosis is a systemic granulomatous disease with unknown etiology. Pulmonary hypertension (PH) is recognized as a complication of usually advanced pulmonary sarcoidosis and associated with increasing mortality. PH in sarcoidosis can occur as consequences of multifactorial conditions, such as interstitial lung disease, granulomatous infiltration, or external compression of the pulmonary artery and myocardial involvement. The exact prevalence of PH in patients with sarcoidosis is unclear and related to disease severity and ethnic differences (1-3). This study aimed to assess the prevalence and characteristics of PH in Turkish patients with sarcoidosis.

**Methods**

**Study population**

This single-center study was conducted at Marmara University, Istanbul. The study included 60 patients with biopsy-proven extra-cardiac sarcoidosis. Patients with poor echogenicity, left ventricular systolic dysfunction (ejection fraction <50%), moder-
ate-to-severe left-sided valvular disease, and other etiologies of PH were excluded. One patient had left ventricular dysfunction, one patient had poor echogenicity, one patient had severe valvular disease, and two patients had pulmonary embolism. After application of the exclusion criteria, the study population consisted of the remaining 55 patients with sarcoidosis.

**Measurements**

Demographic data, including history of systemic hypertension or diabetes, organ involvement, duration of illness, steroid usage, functional capacity using New York Heart Association (NYHA) class, radiological stages (according to chest radiography), and results of pulmonary function testing, were recorded for all patients. Pulmonary function parameters were measured according to the European Respiratory Society recommendations (4). The 6-min walk test (6 MWT) was conducted in accordance with the American Thoracic Society guidelines (5). Pulse oximetry saturations were recorded at the beginning and end of the test. The total walking distances were recorded at the end of the test.

All patients were studied prospectively by transthoracic echocardiography (TTE) to evaluate the probability of PH according to current guidelines (6). Right heart catheterization (RHC) was performed to assess intermediate-to-high probability of PH.

**Echocardiography probability of PH**

All study patients underwent detailed TTE to estimate the probability of PH based on the guidelines of the available device (Epiq 7, Philips Healthcare, Andover, MA, USA) with 3.5 MHz (S5-1) transducer. Digitally stored images were analyzed offline (Xcelera, Philips). The parameters of left and right heart systolic and diastolic functions were measured based on the recommendations (7, 8). Tricuspid regurgitation velocity and other echocardiographic signs were combined to assess the probability of PH as recommended (6). All patients underwent myocardial strain analysis (9).

**Right heart catheterization**

Patients with mean pulmonary arterial pressure (mPAP) >20 mm Hg in RHC were defined as PH based on current recommendations (10). Precapillary PH was defined as mPAP >20 mm Hg, pulmonary capillary wedge pressure (PCWP) ≤15 mm Hg, and pulmonary vascular resistance (PVR) ≥3 WU, whereas mPAP >20 mm Hg and PCWP >15 mm Hg were postcapillary PH. Additionally, postcapillary PH with PVR ≥3 WU was interpreted as combined post- and precapillary PH (10). The cardiac index was calculated using the indirect Fick method.

**Statistical analysis**

SPSS for Windows (version 16.0; SPSS, Chicago, IL, USA) was used to analyze the data. One-sample Kolmogorov–Smirnov test was used to assess the distribution of continuous variables. Normal distributed data were presented as mean±SD, whereas variables not displaying normal distribution were presented as median with interquartile range. Categorical parameters were expressed as frequencies and percentages. The Mann–Whitney U test was used to compare numerical data between low and intermediate–high risk of PH. Categorical parameters were assessed between groups using the χ² test. Significance was determined at p<0.05.

**Results**

Figure 1 shows the study flowchart of patient selection. The remaining 55 patients with sarcoidosis were assessed using echocardiography to estimate the risk of PH. Eight of the patients had intermediate–high risk of PH, and RHC was recommended. Two of intermediate–high risk patients refused to undergo RHC. The remaining six patients underwent RHC, and three of them were incompatible with PH. The prevalence of PH was 5.5% (3/55).

Pulmonary manifestations were present in 96.4% (53/55) of all patients. Steroid and immunomodulatory treatments were administered to 23 (41.8%) and 4 (7.3%) of patients, respectively. Table 1 shows the baseline characteristics of the patients. No differences were found between low and intermediate–high risk PH groups for cardiovascular comorbidities, such as hypertension, diabetes mellitus, or smoking. Patients with intermediate–high risk of PH were older and had higher body mass index (BMI). No differences were found in pulmonary function test parameters between groups. By contrast, patients with inter-
mediate–high risk of PH had worse NYHA class, lower 6 MWD, and higher N-terminal probrain natriuretic peptide (NT-proBNP) levels.

Table 2 shows the echocardiographic parameters of patients. Although no differences were found in left ventricular (LV) ejection fraction between groups, mitral lateral S' wave was lower in patients with intermediate–high risk of PH. LV diastolic parameters, such as transmitral E/A ratio and mitral lateral E' wave, were lower in patients with intermediate–high of PH, and left atrial area was higher. However, right ventricular (RV) functional parameters, such as RV fractional area change and tricuspid annular plane systolic excursion (TAPSE), between groups. Systolic pulmonary artery pressure (SPAP), right atrial pressure (RAP), and tricuspid regurgitation velocity were significantly higher in patients with intermediate–high risk of PH.

Table 3 shows that three of the patients with PH had combined post- and precapillary PH. Two patients with PH had radiologic stage IV. All three patients with PH had low diffusing lung capacity for carbon monoxide (DLCO) level (<65%) and low 6 MWD (<350 m). Without significant systolic and diastolic dysfunction (EF >50% and E/e' <14), three patients with PH had high NT-proBNP level (>125 pg/ml) and markedly low right and left ventricular global longitudinal strain (RV GLS and LV GLS, respectively).

Discussion

This is the first study to evaluate evaluating prospectively and systematically the prevalence of PH in patients with sarcoidosis in a Turkish cohort based on current recommendations (6, 10). This study also demonstrated that several factors might be predictors for PH in patients with sarcoidosis. The prevalence of PH was 5.5%, and none of them had pre-capillary PH. A recent study from Germany reported that the prevalence of PH was 4.5% (3.6% for precapillary PH) (11). This study involved 111 patients with sarcoidosis, and 10 patients underwent RHC based on echocardiographic findings (SPAP ≥30 mm Hg). Another study by a European Caucasian cohort investigated the prevalence of PH in 399 patients with sarcoido-
osis using echocardiography signs, similar to our study design, and 28 patients underwent RHC. The estimated prevalence of PH in this cohort was 2.5% (2.3% for precapillary PH) (1). Alhamad et al. investigated the prevalence of PH in Arab patients (2). Echocardiography was used to retrospectively analyze 96 patients with sarcoidosis, and PH was accepted as SPAP ≥40 mm Hg. RHC was not performed. The prevalence 20%, with a predominance of female patients, similar to our study results. Shorr et al. (3) reported that the prevalence of PH was 73.8% in patients with advanced sarcoidosis who were candidates for lung transplantation, of which 65% and 70% were women and African Americans, respectively (3). The PH prevalence of 5.5% was low in our population. This might be influenced by the study design, wherein only intermediate–high probability patients with PH underwent RHC due to ethical considerations. Furthermore, our study population included those with advanced disease (10/55). Moreover, ethnic differences might affect the prevalence of PH.

The mechanisms of PH in sarcoidosis are multifactorial and may develop as a consequence of interstitial lung disease, granulomatous infiltration, or external pulmonary artery compression or myocardial involvement. During the 6th World Symposium on Pulmonary Hypertension, sarcoidosis was classified into group 5 remaining different conditions (10). Our study showed that all three patients had combined post- and precapillary PH. Without clinically overt cardiac involvement

### Table 2. Echocardiographic parameters of all patients with low and intermediate risk of PH

|                         | All patients with sarcoidosis (n=55) | Low risk of PH on echo (n=47) | Intermediate–high risk of PH on echo (n=8) | P-value* |
|-------------------------|-------------------------------------|------------------------------|-------------------------------------------|---------|
| LVEDD (mm)              | 44.8±4.3                           | 44.8±4.1                     | 44.7±5.5                                  | 0.977   |
| LVEDD (mm)              | 28.2±3.9                           | 28.2±3.9                     | 29.6±5.3                                  | 0.547   |
| LV EF (%)               | 65.3±6.5                           | 65.7±6.1                     | 62.9±8.4                                  | 0.110   |
| RV basal diameter (mm)  | 30.2±3.7                           | 29.8±3.7                     | 32.2±3.0                                  | 0.040   |
| RV/LV ratio             | 0.7±0.1                            | 0.7±0.1                      | 0.7±0.1                                   | 0.983   |
| LAA (cm²)               | 15.2±3.5                           | 14.6±3.1                     | 18.6±3.9                                  | 0.006   |
| RAA (cm²)               | 12.9±2.7                           | 12.6±2.8                     | 14.7±1.9                                  | 0.019   |
| Septum (mm)             | 10.1±1.5                           | 9.8±1.4                      | 11.1±1.5                                  | 0.019   |
| LV mass (gr)            | 148.0±34.8                         | 145.2±33.6                   | 164.3±39.7                                | 0.231   |
| LV wall thickness (mm)  | 4.8±0.9                            | 4.7±0.6                      | 5.9±1.7                                   | 0.029   |
| PA diameter (mm)        | 20.6±2.4                           | 20.3±2.3                     | 22.7±1.7                                  | 0.004   |
| Transmirtal E velocity (cm/s) | 0.8±0.2 | 0.8±0.2                      | 0.8±0.4                                   | 0.178   |
| Transmirtal E-wave DT (ms) | 200.5±40.4 | 196.7±33.5                    | 222.4±67.9                                | 0.098   |
| Transmirtal E/A ratio   | 1.0±0.3                            | 1.1±0.3                      | 0.9±0.1                                   | 0.041   |
| Mitral lateral E’ (cm/s) | 11.2±3.7 | 11.7±3.6                     | 7.9±2.4                                   | 0.004   |
| Mitral lateral S’ (cm/s) | 10.8±2.9 | 11.2±2.9                     | 8.3±1.9                                   | 0.009   |
| E/E’ ratio (cm/s)       | 7.5±2.9                            | 7.0±2.1                      | 9.9±5.2                                   | 0.081   |
| Tricuspid lateral S’ (cm/s) | 12.9±2.3 | 12.8±2.1                     | 13.5±3.4                                  | 0.552   |
| TAPSE (cm)              | 22.9±4.0                           | 23.0±3.9                     | 22.1±5.1                                  | 0.587   |
| RV FAC (%)              | 45.4±8.9                           | 46.6±8.5                     | 38.6±8.8                                  | 0.018   |
| RV outflow acceleration time (m/s) | 119.3±27.7 | 122.7±25.1                   | 99.5±5.0                                  | 0.069   |
| Tricuspid regurgitation velocity (m/s) | 2.3±0.4 | 2.2±0.3                      | 3.1±0.5                                   | <0.001  |
| RAP (mm Hg)             | 3.2±0.9                            | 3.0                          | 4.3±2.3                                   | 0.001   |
| SPAP (mm Hg)            | 25.8±9.6                           | 22.9±5.1                     | 42.8±2.3                                  | <0.001  |
| VCI collapse <50%       | 1 (1.8%)                           | -                            | 1 (12.5%)                                 | 0.142   |
| RV outflow midsystolic notch | 2 (3.8%) | -                          | 2 (25%)                                   | 0.010   |
| PR velocity >2.2 m/s    | 1 (1.8%)                           | -                            | 1 (12.5%)                                 | 0.142   |
| RV outflow VTI          | 18.3±3.6                           | 18.5±3.6                     | 17.5±3.9                                  | 0.366   |
| LV GLS (%)              | -16.9±3.8                          | -17.2±3.7                    | -15.1±4.0                                 | 0.143   |
| RV GLS (%)              | -18.9±5.9                          | -17.8±4.7                    | -14.3±5.3                                 | 0.086   |

*Comparison of low and intermediate–high risk of PH

DT - deceleration time; EF - ejection fraction; FAC - fractional area change; LAA - left atrium area; LV - left ventricular; LVEDD - LV end-diastolic diameter; LVEDD - LV end-diastolic diameter; LV GLS - left ventricular global longitudinal strain; PY - pulmonary valve regurgitation; RAA - right atrium area; RAP - right atrial pressure estimated by VCI collapse; RV - Right ventricular; RV GLS - RV global longitudinal strain; sPAB - systolic pulmonary artery pressure measured by tricuspid valve regurgitation velocity; TAPSE - tricuspid annular plane systolic excursion; VCI - vena cava inferior; VTI - velocity time integral.
Cardiac conditions that are substrates for PH due to left heart failure (16, 17). Furthermore, obesity causes pulmonary and systemic effects, with higher BMI being associated with PH based on previous studies (18, 19). In our study, the patients with intermediate–high risk of PH were significantly older and had higher BMI compared with those with low risk of PH. However, three patients with PH were >60 years, and two of them were morbidly obese (BMI >35 kg/m²). Comorbid conditions such as elderly and obesity can cause PH in patients with sarcoidosis.

**Study limitations**

First, this study was limited by the sample size of patients with sarcoidosis. Second, all patients did not undergo RHC because of ethical considerations, which might affect the prevalence of PH in the cohort. Third, cardiac magnetic resonance imaging or positron emission tomography was not used to estimate cardiac involvement, which might explain the etiology of PH. Finally, 49% of patients were on immunosuppressive therapy, which might influence the hemodynamic parameters.

**Conclusion**

The prevalence of PH in patients with sarcoidosis was 5.5% in a Turkish cohort. In addition to recommended echocardiographic parameters to assess the probability of PH, diastolic function parameters, RV and LV GLS, and clinical parameters, such as NT-proBNP and 6 MWD, can be used for early detection of sarcoidosis-related PH.

**Conflict of interest:** None declared.

**Peer-review:** Externally peer-reviewed.

**Authorship contributions:** Concept – D.K.Ö., B.M.; Design – D.K.Ö., B.M.; Supervision – D.K.Ö., B.M., B.C.; Fundings – D.K.Ö., B.M., D.K., S.S.Ş.; Materials – D.K.Ö., B.M., D.K., B.C.; Data collection and/or processing – D.K.Ö., B.M., B.C.; Analysis and/or interpretation – D.K.Ö., B.M., B.T.; Literature search – D.K.Ö., B.T., S.S.Ş.; Writing – D.K.Ö., B.T.; Critical review – D.K.Ö., B.M., D.K., B.C., S.S.Ş., B.C.

### References

1. Huitema MP, Bakker ALM, Mager JJ, Rensing BJWM, Smits F, Sniijder RJ, et al. Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study. Eur Respir J 2019; 54: 1900897. [CrossRef]
2. Alhamad EH, Idrees MM, Alanezi MO, Alboukai AA, Shaik SA. Sarcoidosis-associated pulmonary hypertension: Clinical features and outcomes in Arab patients. Ann Thorac Med 2010; 5: 86–91. [CrossRef]
3. Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25: 783–8.
4. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al.; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005; 26: 319–38.

**Table 3. Characteristics of the three patients with pulmonary hypertension**

| PH patients | 1       | 2       | 3       |
|-------------|---------|---------|---------|
| Echocardiographic probability of PH | High    | Intermediate | High    |
| Age (years) | 63      | 62      | 67      |
| Sex         | Female  | Female  | Female  |
| BMI (kg/m²) | 36.2    | 41.6    | 28.4    |
| Hypertension | +       | -       | -       |
| Radiologic stage | IV      | I       | IV      |
| Duration of sarcoidosis (years) | 4       | 10      | 8       |
| Steroid using | +       | +       | +       |
| NYHA class   | IV      | II      | IV      |
| DLCO         | 62      | 63      | 61      |
| 6 MWD (m)    | 270     | 225     | 306     |
| Desaturation during 6 MWT | +       | -       | +       |
| NT-proBNP (pg/mL) | 314     | 3551    | 2065    |
| EF (%)       | 61      | 74      | 66      |
| E/e’ ratio   | 7.3     | 7.5     | 10      |
| TAPSE        | 21      | 18.9    | 16      |
| FAC (%)      | 32.6    | 29.6    | 23.8    |
| RV EF (%)    | 30      | 27.9    | 40.7    |
| RV GLS (%)   | -13     | -9.8    | -10.3   |
| RA res. (%)  | 13      | 24      | 15.6    |
| LV GLS (%)   | -17.7   | -13.2   | -13.4   |
| mPAP (mm Hg) | 50      | 33      | 45      |
| PVR (WU)     | 6       | 3       | 13      |
| PCWP (mm Hg) | 22      | 21      | 18      |
| DPG (mm Hg)  | 10      | 0       | 13      |
| CI (L/min/m²)| 1.9     | 1.7     | 2.03    |

(BMI >50%), three patients had impaired LV and RV GLS, which might be a consequence of atelectasis or interventricular septal wall fibrosis. In our study, the patients with intermediate–high risk of PH were significantly older and had higher BMI compared with those with lower risk of PH. However, three patients with PH were >60 years, and two of them were morbidly obese (BMI >35 kg/m²). Comorbid conditions such as elderly and obesity can cause PH in patients with sarcoidosis.

(EF >50%), three patients had impaired LV and RV GLS, which might be a consequence of atelectasis or interventricular septal wall fibrosis. In our study, the patients with intermediate–high risk of PH were significantly older and had higher BMI compared with those with lower risk of PH. However, three patients with PH were >60 years, and two of them were morbidly obese (BMI >35 kg/m²). Comorbid conditions such as elderly and obesity can cause PH in patients with sarcoidosis.

(EF >50%), three patients had impaired LV and RV GLS, which might be a consequence of atelectasis or interventricular septal wall fibrosis. In our study, the patients with intermediate–high risk of PH were significantly older and had higher BMI compared with those with lower risk of PH. However, three patients with PH were >60 years, and two of them were morbidly obese (BMI >35 kg/m²). Comorbid conditions such as elderly and obesity can cause PH in patients with sarcoidosis.
5. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111–7. [CrossRef]

6. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 903–75.

7. Lang RM, Badano LP, Mor-Avi V, Afifi A, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1–39. [CrossRef]

8. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edwards T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 29: 277–314. [CrossRef]

9. Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr 2015; 28: 183–93. [CrossRef]

10. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatouli MA, Krowka M, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913. [CrossRef]

11. Pabst S, Hammerstingl C, Grau N, Kreuz J, Grohe C, Juergens UR, et al. Pulmonary arterial hypertension in patients with sarcoidosis: the Pulsar single center experience. Adv Exp Med Biol 2013; 755: 299-305. [CrossRef]

12. Tigen K, Sunbul M, Karahmet T, Tasar O, Dundar C, Yalcinsoy M, et al. Early Detection of Bi-ventricular and Atrial Mechanical Dysfunction Using Two-Dimensional Speckle Tracking Echocardiography in Patients with Sarcoidosis. Lung 2015; 193: 669–75. [CrossRef]

13. Kaptan Ozen D, Mutlu B, Kocakaya D, Turan B, Sert Sekerci S, Ceyhan B, et al. The effect of global longitudinal strain on impaired six-minute walk test performance in patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37: 66–73.

14. Ayinapudi K, Singh T, Motwani A, Le Jemtel TH, Oparil S. Obesity and Pulmonary Hypertension. Curr Hypertens Rep 2018; 20: 99.

15. Mirsaeidi M, Omar HR, Baughman R, Machado R, Sweiin N. The association between BNP, 6MWD test, DLCO% and pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2016; 33: 317–20.

16. McArdle JR, Trow TK, Lerz K. Pulmonary hypertension in older adults. Clin Chest Med 2007; 28: 717–33. [CrossRef]

17. Berra G, Noble S, Soccal PM, Beghetti M, Lador F. Pulmonary hypertension in the elderly: a different disease? Breathe (Sheff) 2016; 12: 43–9. [CrossRef]

18. Ayinapudi K, Singh T, Motwani A, Le Jemtel TH, Oparil S. Obesity and Pulmonary Hypertension. Curr Hypertens Rep 2018; 20: 99.

19. Pons AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest 2013; 144: 169–76. [CrossRef]